Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K / AKT / NF‐κB signalling pathway
Nephrology · 2023
DOI: 10.1111/nep.14159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2023. Verfasst von Ziyuan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Wuhan Polytechnic University, Wuhan, China. Hauptthemen laut MEDLINE: NF-kappa B, Hyperuricemia. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Hubei Provincial Key Laboratory of Animal Nutrition and Feed Science Open Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aim
Inflammation and apoptosis are main pathological processes that lead to the development of hyperuricemic nephropathy (HN). This study aims to explore whether baicalin (BA) and baicalein (BAI) can relieve the damage through PI3K/AKT/NF‐κB signal pathway and provide more reliable and precise evidence for the treatment of HN.
Methods
HN mice were induced by yeast extract with potassium oxonate (PO), and HK‐2 cells were induced by monosodium urate (MSU). Molecular docking, western blot, q‐PCR, and other methods were used to explore the changes of various indicators in HN mice and HK‐2 cells.
Results
Molecular docking results showed that BA and BAI had good binding ability with PI3K, AKT, p65 and IκBα. BA and BAI significantly ameliorated the levels of renal function, decreased the p‐PI3K, p‐AKT and p‐p65 expression, down‐regulated the BAX/BCL2 and CASP3, and blunted the mRNA levels of tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β, and IL‐18 in both renal tissue of HN mice and HK‐2 cells induced by MSU. BA and BAI also decreased the oxidative stress level of MSU‐induced HK‐2 cells.
Conclusion
BA and BAI were confirmed to attenuate HN through alleviating renal inflammatory and apoptosis in cells and tissues by inhibiting PI3K/AKT/NF‐κB pathway. BA and BAI were expected to be developed as new anti‐HN drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, Wuhan Polytechnic University, Wuhan, China.
- School of Animal Science and Nutrition Engineering, Wuhan Polytechnic University, Wuhan, China.
- School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China.
ORCID-Profile: Lingyun Xu
Förderung
- Hubei Provincial Key Laboratory of Animal Nutrition and Feed Science Open Project
- National Natural Science Foundation of China
Zitieren
APA
Liu, Z., Xiang, H., Deng, Q., Fu, W., Li, Y., Yu, Z., Qiu, Y., Mei, Z., & Xu, L. (2023). Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K / AKT / NF‐κB signalling pathway. Nephrology. https://doi.org/10.1111/nep.14159
Vancouver
Liu Z, Xiang H, Deng Q, Fu W, Li Y, Yu Z, et al. Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K / AKT / NF‐κB signalling pathway. Nephrology. 2023. doi:10.1111/nep.14159
BibTeX
@article{Liu2023,
author = {Liu, Ziyuan and Xiang, Huilong and Deng, Qin and Fu, Wanting and Li, Yang and Yu, Zejun and Qiu, Yinsheng and Mei, Zhinan and Xu, Lingyun},
title = {Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K / AKT / NF‐κB signalling pathway},
journal = {Nephrology},
year = {2023},
doi = {10.1111/nep.14159}
}
EUVIMED